Bausch Health(US:BHC)2023-05-03 16:00Debt and Financial Obligations - As of March 31, 2023, the company had $13,715 million in outstanding fixed rate debt and $5,382 million in variable rate debt[702]. - The estimated fair value of the company's issued fixed rate debt as of March 31, 2023 was $8,679 million[702]. - The company is required to pay commitment fees of 0.25%-0.50% per annum on unutilized commitments under the 2027 Revolving Credit Facility[118]. - As of March 31, 2023, the company's outstanding foreign currency exchange contracts had an aggregate notional amount of $548 million[111]. Revenue and Market Conditions - Xifaxan revenues represent approximately 80% of the Salix reporting unit's revenue, and uncertainties regarding legal decisions could impact future revenues[115]. - The company continues to monitor conditions impacting the valuation of its Dermatology and Neurology reporting units, which had no headroom as of September 30, 2022, and October 1, 2022, respectively[106][108]. - The company has not identified any changes that would suggest the fair value of its reporting units is less than their carrying value, but future impairment charges may be necessary if market conditions deteriorate[106][108]. Interest Rate Sensitivity - A 100 basis-point increase in interest rates would have an annualized pre-tax effect of approximately $54 million on the company's earnings and cash flows[702]. Shareholder Information - The company had 363,723,880 issued and outstanding common shares as of April 28, 2023[105]. Risk Factors - There have been no material changes to the risk factors disclosed in the Annual Report for the year ended December 31, 2022[707].